このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Silk Road Medical 配当金

配当金基準チェック /06

Silk Road Medical配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り	1.8%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-US$1.34
3年後の配当利回り予想	0%

最近の配当金アップデート

更新なし

Recent updates

Silk Road Medical, Inc (NASDAQ:SILK) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

May 03

Is Silk Road Medical (NASDAQ:SILK) A Risky Investment?

May 02

Silk Road Medical, Inc's (NASDAQ:SILK) Shares Leap 35% Yet They're Still Not Telling The Full Story

Feb 03

A Piece Of The Puzzle Missing From Silk Road Medical, Inc's (NASDAQ:SILK) 26% Share Price Climb

Dec 20

Is Silk Road Medical (NASDAQ:SILK) Weighed On By Its Debt Load?

Nov 03

Is Silk Road Medical (NASDAQ:SILK) A Risky Investment?

Aug 05

Shareholders Should Be Pleased With Silk Road Medical, Inc's (NASDAQ:SILK) Price

May 05

Silk Road Medical GAAP EPS of -$0.44 beats by $0.02, revenue of $33.17M beats by $2.14M

Jul 26

Silk Road Medical: Divergence From Alternative Risk Premia Means Lack Of Upside Capture

Jul 19

Silk Road Medical falls after Citigroup downgrades to Sell from Neutral

Jul 11

Is Silk Road Medical (NASDAQ:SILK) Using Too Much Debt?

Jun 09

Silk Road Medical - What A Road It Has Been

Apr 08

決済の安定と成長

配当データの取得

安定した配当: SILKの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: SILKの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Silk Road Medical 配当利回り対市場

SILK 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (SILK)	n/a
市場下位25% (US)	1.5%
市場トップ25% (US)	4.8%
業界平均 (Medical Equipment)	1.8%
3年後のアナリスト予想 (SILK)	0%

注目すべき配当: SILKは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: SILKは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: SILKの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: SILKが配当金を報告していないため、配当金の持続可能性を計算できません。

Silk Road Medical 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Recent updates

New minor risk - Shareholder dilution

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Silk Road Medical, Inc (NasdaqGS:SILK) for $1.2 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Silk Road Medical, Inc (NasdaqGS:SILK) for $1.2 billion.

Price target increased by 13% to US$20.83

Silk Road Medical, Inc (NASDAQ:SILK) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2024

Is Silk Road Medical (NASDAQ:SILK) A Risky Investment?

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Silk Road Medical, Inc, Annual General Meeting, Jun 18, 2024

Silk Road Medical, Inc to Report Q1, 2024 Results on Apr 30, 2024

Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuro Protection System Plus

CFO & COO recently sold US$170k worth of stock

CFO & COO notifies of intention to sell stock

Silk Road Medical Expands TCAR Portfolio with Launch of Tapered Enroute®? Transcarotid Stent System

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2024

Silk Road Medical, Inc to Report Q4, 2023 Results on Feb 28, 2024

Silk Road Medical, Inc's (NASDAQ:SILK) Shares Leap 35% Yet They're Still Not Telling The Full Story

Insufficient new directors

A Piece Of The Puzzle Missing From Silk Road Medical, Inc's (NASDAQ:SILK) 26% Share Price Climb

New minor risk - Shareholder dilution

Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Silk Road Medical Announces Chief Executive Officer Changes

Is Silk Road Medical (NASDAQ:SILK) Weighed On By Its Debt Load?

Silk Road Medical, Inc to Report Q3, 2023 Results on Nov 08, 2023

Price target decreased by 39% to US$20.88

Erica J. Rogers to Retire as Chief Executive Officer of Silk Road Medical, Inc

Erica J. Rogers to Retire as President of Silk Road Medical, Inc

Chief Commercial Officer recently sold US$146k worth of stock

Chief Commercial Officer notifies of intention to sell stock

Is Silk Road Medical (NASDAQ:SILK) A Risky Investment?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Silk Road Medical, Inc to Report Q2, 2023 Results on Aug 01, 2023

President notifies of intention to sell stock

Price target decreased by 8.6% to US$51.67

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Silk Road Medical, Inc Provides Revenue Guidance for the Year 2023

Chief Commercial Officer exercised options and sold US$261k worth of stock

Shareholders Should Be Pleased With Silk Road Medical, Inc's (NASDAQ:SILK) Price

President exercised options and sold US$229k worth of stock

Chief Commercial Officer exercised options and sold US$234k worth of stock

Is Silk Road Medical (NASDAQ:SILK) A Risky Investment?

President exercised options and sold US$244k worth of stock

President recently sold US$850k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$296k worth of stock

Silk Road Medical, Inc to Report Q4, 2022 Results on Feb 28, 2023

Chief Commercial Officer exercised options and sold US$333k worth of stock

CFO & COO exercised options and sold US$3.9m worth of stock

President exercised options and sold US$300k worth of stock

Chief Commercial Officer exercised options and sold US$341k worth of stock

President exercised options and sold US$523k worth of stock

Price target increased to US$55.00

Chief Commercial Officer exercised options and sold US$347k worth of stock

CFO & COO exercised options and sold US$1.2m worth of stock

Silk Road Medical, Inc Provides Earnings Guidance for the Full Year 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Chief Commercial Officer exercised options and sold US$288k worth of stock

Silk Road Medical, Inc to Report Q3, 2022 Results on Nov 08, 2022

Silk Road Medical, Inc has completed a Follow-on Equity Offering in the amount of $100.000026 million.

Silk Road Medical, Inc Provides Earnings Guidance for the Quarter Ended September 30, 2022

Silk Road Medical announces $100M common stock offering

President exercised options and sold US$407k worth of stock

Chief Commercial Officer exercised options and sold US$292k worth of stock

Is Silk Road Medical (NASDAQ:SILK) Using Too Much Debt?

President exercised options and sold US$420k worth of stock

Silk Road Medical, Inc. Announces First Patient Enrolled in ROADSTER 3 Post Approval Study Evaluating TCAR® System in Treatment of Standard Surgical Risk Patients

Chief Commercial Officer exercised options and sold US$253k worth of stock

CFO & COO exercised options and sold US$681k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2022

Silk Road Medical GAAP EPS of -$0.44 beats by $0.02, revenue of $33.17M beats by $2.14M

Silk Road Medical: Divergence From Alternative Risk Premia Means Lack Of Upside Capture

配当金基準チェック /06